Only three months after the entry of healthcare-focused investment firm ArchiMed, Suanfarma has reached an agreement to acquire a majority of Monteloeder, a world leader in the research and development of scientifically proven and patent-protected botanical extracts supported by clinical studies.
Monteloeder has an excellent reputation and legacy of trust in the nutraceutical and functional foods categories across the globe. Quality, science, and innovation are the three pillars of the development powerhouse, located in the Spanish Mediterranean region, with rich botanical raw materials of high-value health properties.
With over 25 years in the market, Monteloeder has experienced strong international growth with a relevant presence in the USA and several Asian countries. Suanfarma aims to expand Monteloeder’s product offering into the group’s core markets and capitalize on Monteloeder’s market-leading R&D Department to strengthen the development of scientifically proven branded ingredients.
The transaction, which value has not been disclosed, implies the expansion of Suanfarma as part of its growth, increasing significantly its industrial and development capacity.
During the last years, Suanfarma has achieved the highest growth in its history and has acquired new companies in Spain, Portugal, Colombia and Italy, increasing significantly its industrial and development capacity.
KPMG Abogados advised Suanfarma on this deal with a Valencia office team comprising directors Andrés Iñigo Fuster and Jaime de la Rosa, and partner Francisco Fernández, who provided Legal, Tax and Labour advice respectively.
On the other hand, Alicante-based law firm Galán & Asociados has advised Elche-based company Monteloeder on its integration into Suanfarma. Galán & Asociados Corporate Finance department team was led by the founding partner José Antonio Galán (pictured left).
